Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RJ4287 Tablets Phase IIa Study in Adults With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
CTR20254632Phase 2Active
- Sponsor
- Olympus Pharmaceutical
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rj4287 in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Olympus Pharmaceutical. Primary endpoint: Safety and tolerability. Started Dec 2025; status: active.
02
Drugs
rj4287
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20254632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254632.